The global Next-Generation Sequencing (NGS) Market is undergoing an unprecedented technological and clinical renaissance, transitioning from basic academic research to frontline diagnostic medicine and personalized oncology. According to a comprehensive market intelligence report released by Stellar Market Research, the Next-Generation Sequencing Market was valued at USD 12.65 billion in 2024 and is projected to skyrocket to USD 34.11 billion by 2032, expanding at a robust compound annual growth rate (CAGR) of 13.2% during the forecast period. Key Findings from the Report Market Valuation & Growth: The market reached USD 12.65 billion in 2024 and is on track to hit USD 34.11 billion by 2032, maintaining a dynamic 13.2% CAGR from 2025 to 2032. Segment Dominance: Whole Genome Sequencing (WGS) and Targeted Sequencing & Re-sequencing dominate the technology landscape, driven by comprehensive profiling needs in oncology and rare disease diagnostics. Fastest-Growing Segment: RNA Sequencing and long-read sequencing technologies (such as PacBio SMRT and Oxford Nanopore platforms) are witnessing the fastest adoption rates, propelled by the need to capture complex transcriptomic variations and structural genomic changes. Regional Leadership: North America commands the largest market share, anchored by advanced clinical laboratory infrastructure, a high concentration of market pioneers like Illumina and Thermo Fisher Scientific, and robust federal initiatives like the NIH All of Us research program. Emerging Hotspot: Asia-Pacific represents the fastest-growing and most high-potential regional market, energized by mega-scale national projects such as China’s 100M Genome Plan and India's Genome India Project, alongside rapid expansion by regional biotech powerhouses like BGI. For further information, click the following link:https://www.stellarmr.com/report/req_sample/next-generation-sequencing-market/2661
Topics
